AMCS unveils the AMCS Platform Summer ‘23 edition, the second release this year, delivering exciting new productivity features and a dynamic customer experience for environmental, transportation, waste, recycling and resource operators
10.7.2023 18:15:00 EEST | Business Wire | Press release
AMCS, the world leading technology provider for the environmental, waste, recycling and environmental health and safety industries, today announced the global launch of the AMCS Platform 2023 Summer release. The release offers important new benefits and features, including:
- Order-to-Cash Automation to simplify and accelerate cashflow – Newly streamlined and optimised processes enable operators to invoice faster and more easily, so they can get paid sooner, creating a better experience for both users and customers. A new cash collection management module provides automated credit control to collect all receivables.
-
Maximised Asset Utilisation – The new Equipment Inventory module optimises visibility and control over container assets by quickly identifying slow-moving containers, ensuring they’re available to meet market demand, and allowing operators to optimise sales and minimise the costs associated with the physical loss of containers.
Significant enhancements to the Transport Solutions platform user experience will boost scheduling and maintenance productivity of both fleet owners and planners, empowering them to optimise utilisation of company fleet assets.
- Digitalisation of Purchase to Pay – A streamlined process will allow recyclers to seamlessly manage tickets for the purchase of feedstock. Scrap recyclers can capture supplier data quickly and easily to ensure regulatory compliance. Integrated, flexible supplier payments allow cash (including ATM), check, and ACH, as well as exciting emerging digital instant payment types (using AMCS Pay) including push-to-debit and pre-paid cards. These connected, digitalised processes will automate, connect, and accelerate purchasing, compliance, scale, supplier payment, and financial tasks, boosting both efficiency and competitiveness.
“Our continued investment in automation processes is the major theme of the AMCS Platform. The Summer ’23 release delivers real business value,” says Elaine Treacy, Global Product Director at AMCS. Treacy continues, “Newly optimised ‘order to cash’ processes will drive faster payments with less effort, reducing the risk of overdue payments and bad debt. Our new streamlined ‘purchase to pay‘enables recyclers to purchase feedstock in an efficient and regulatory compliant manner. In addition to supplier settlements using cash and checks, we are introducing exciting digital payment options.”
The investment in enhanced user experiences and a new equipment inventory feature will allow AMCS customers to drive greater utilisation and financial return from their container and truck assets, and thus improve their sales. Other highlights of the summer release include:
- Full integration of AMCS Vision AI into the AMCS Platform, providing new dashboards for insight as well as options to automatically charge for exceptions such as overfills and contamination.
- A new Sustainability Dashboard on the AMCS Customer Portal, allowing customers to share key sustainability performance metrics with their end users.
- New Customer Self-Serve features, including support for Interactive Voice Response (IVR) for PCI compliant payments and the digital exchange of Duty of Care (UK) compliance documentation.
- For municipal operators, more streamlined invoice processing of direct residential subscribers and enhanced controls on the service status of customers, depending on their payment standing.
- A new and improved AMCS Academy online customer training platform, with more compelling and engaging training experiences.
To learn more about AMCS Platform Summer ‘23 Release, visit www.amcsgroup.com
About AMCS Group
AMCS, with offices in Europe, North America and Australia is a global technology leader for the environmental, waste, recycling, and resource industries. We help over 4,000 customers reduce their operating costs, increase asset utilisation, optimise margins, drive sustainability, and improve customer service. Our enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world. Read more about AMCS at www.amcsgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230628408946/en/
Contact information
Austen Lees
Sirius Communications
austen@siriuscomms.co.uk
Tel.: 00447773813210
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
